Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Consensus Recommendation of “Moderate Buy” by Analysts

Axsome Therapeutics, Inc. (NASDAQ:AXSM) has earned a consensus rating of “Moderate Buy” from the twenty-one research firms that are presently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating and nineteen have assigned a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $203.1667.

Several analysts recently issued reports on AXSM shares. Wells Fargo & Company raised their target price on Axsome Therapeutics from $157.00 to $193.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 13th. Mizuho set a $217.00 price objective on Axsome Therapeutics in a research report on Wednesday, December 31st. Robert W. Baird set a $209.00 target price on Axsome Therapeutics in a report on Tuesday, January 13th. TD Cowen reiterated a “buy” rating on shares of Axsome Therapeutics in a report on Wednesday, December 31st. Finally, Royal Bank Of Canada upped their price objective on shares of Axsome Therapeutics from $212.00 to $219.00 and gave the stock an “outperform” rating in a report on Wednesday.

Insider Buying and Selling

In other news, CFO Nick Pizzie sold 12,000 shares of the stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $187.92, for a total value of $2,255,040.00. Following the completion of the transaction, the chief financial officer owned 42,588 shares of the company’s stock, valued at approximately $8,003,136.96. This represents a 21.98% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Herriot Tabuteau sold 91,705 shares of Axsome Therapeutics stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $132.34, for a total value of $12,136,239.70. Following the sale, the chief executive officer owned 7,229 shares in the company, valued at $956,685.86. This represents a 92.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 440,403 shares of company stock valued at $67,191,178 over the last three months. Corporate insiders own 22.30% of the company’s stock.

Hedge Funds Weigh In On Axsome Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in AXSM. Allworth Financial LP grew its position in shares of Axsome Therapeutics by 6.6% in the 3rd quarter. Allworth Financial LP now owns 1,442 shares of the company’s stock worth $175,000 after buying an additional 89 shares during the period. Moors & Cabot Inc. boosted its stake in Axsome Therapeutics by 4.5% during the second quarter. Moors & Cabot Inc. now owns 2,330 shares of the company’s stock worth $243,000 after acquiring an additional 100 shares in the last quarter. Meridian Wealth Management LLC grew its holdings in Axsome Therapeutics by 0.5% in the third quarter. Meridian Wealth Management LLC now owns 22,124 shares of the company’s stock worth $2,687,000 after purchasing an additional 103 shares during the period. GAMMA Investing LLC increased its stake in shares of Axsome Therapeutics by 65.4% during the fourth quarter. GAMMA Investing LLC now owns 268 shares of the company’s stock valued at $49,000 after purchasing an additional 106 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Axsome Therapeutics by 1.1% during the second quarter. China Universal Asset Management Co. Ltd. now owns 9,889 shares of the company’s stock valued at $1,032,000 after purchasing an additional 107 shares during the last quarter. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Key Headlines Impacting Axsome Therapeutics

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Piper Sandler is bullish ahead of a likely Auvelity label expansion by April 30, which would expand the approved uses for Axsome’s depression drug and could materially increase addressable market and sales expectations. Piper Sandler Bullish on Axsome Therapeutics (AXSM) Ahead of Likely Auvelity Label Expansion by April 30
• Positive Sentiment: HC Wainwright has increased some earnings estimates and reiterated a Buy rating with a $260 target, signaling conviction in Axsome’s medium-term revenue trajectory and valuation upside. This analyst support is likely propping up investor sentiment despite volatility. HC Wainwright Brokers Increase Earnings Estimates for AXSM
• Positive Sentiment: Related coverage from HC Wainwright and other outlets highlights expectations for strong price appreciation and has coincided with recent share strength, providing momentum that could support further gains if clinical and label catalysts materialize. HC Wainwright Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) Stock
• Positive Sentiment: Axsome recently hit a new 12‑month high following analyst upgrades, reflecting elevated optimism from the sell side which can attract momentum and institutional interest. Axsome Therapeutics (NASDAQ:AXSM) Hits New 12-Month High Following Analyst Upgrade
• Neutral Sentiment: Analyst roundup pieces summarize diverse views from ~14 analysts; consensus leans positive but shows dispersion in price targets and timing, indicating investor outcomes depend heavily on upcoming regulatory/label and sales data. 3AXSM : Expert Outlook: Axsome Therapeutics Through The Eyes Of 14 Analysts
• Negative Sentiment: HC Wainwright’s detailed model changes are mixed — while they raised several quarterly and FY2025 estimates and the target, they also trimmed forecasts for certain quarters (notably Q2 and Q3 adjustments). That mix introduces near-term earnings uncertainty that can create volatility until clinical/label outcomes and actual sales datapoints arrive.

Axsome Therapeutics Stock Down 0.5%

Shares of NASDAQ AXSM opened at $185.96 on Friday. The firm’s fifty day moving average is $159.39 and its 200 day moving average is $133.27. Axsome Therapeutics has a 52 week low of $86.99 and a 52 week high of $191.50. The company has a quick ratio of 1.50, a current ratio of 1.57 and a debt-to-equity ratio of 1.66. The company has a market cap of $9.37 billion, a price-to-earnings ratio of -39.82, a PEG ratio of 9.80 and a beta of 0.44.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings results on Monday, November 3rd. The company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.12). The firm had revenue of $170.99 million during the quarter, compared to the consensus estimate of $162.96 million. Axsome Therapeutics had a negative return on equity of 277.31% and a negative net margin of 40.90%.Axsome Therapeutics’s revenue was up 63.2% on a year-over-year basis. On average, equities research analysts expect that Axsome Therapeutics will post -2.79 earnings per share for the current year.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.